A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
This study evaluates a novel agent, SB-061, for the treatment of osteoarthritis of the knee. Half of the patients will receive the agent via intra-articular injection and half will receive a placebo injection.

Detailed Description
-----------------
The treatment of pain associated with osteoarthritis may include periodic intra-articular injections of corticosteroids or viscosupplements such as hyaluronic acid. SB-061 is anticipated to relieve osteoarthritis pain by reinforcing the cartilage matrix and providing a lubricating coating of the cartilage. Subjects will receive 1 intra-articular injection of either SB-061 or placebo and be followed for 3 months to evaluate pain amelioration. Subjects and Investigators are blinded to treatment allocation.

Official Title
-----------------
A Placebo-controlled, Double-blind, Randomized Trial of a Single Intra-articular Delivery of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Device: SB-061
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Femorotibial osteoarthritis of the knee Radiological OA Kellgren-Lawrence grade 2 or 3 WOMAC Pain 1 score of the target knee of ≥4 and ≤ 9 Exclusion Criteria: Hypersensitivity to medications or to intra-articular injections Intra-articular delivery of corticosteroids or hyaluronic acid in the target knee within 6 months of study High dose systemic corticosteroid treatment of longer (>14 days) duration w/in 6 months of study Major surgery or arthroscopy of the target knee within year prior to study Planned surgery in the target knee within the next 3 months Concomitant inflammatory disease affecting either knee

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SB-061<br>SB-061 | Device: SB-061<br>* delivered via intra-articular injection<br>|
| Placebo Comparator: Placebo<br>Placebo | Other: Placebo<br>* Placebo delivered via intra-articular injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain (A1) scores from baseline to 4 weeks post treatment will be compared between treatment and control groups. | Baseline, 4 weeks | 
| Incidence of Treatment-Emergent Adverse Events | A summary of Treatment-Emergent Adverse Events will be reported | Through 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) sub-scores scores related to pain from baseline to 4 weeks post treatment will be compared between treatment and control groups. | Baseline, 4 weeks | 
| Physical function | Change in Patient Global Assessement scores from baseline to 4 weeks post treatment will be compared between treatment and control groups. | Baseline, 4 weeks | 
| Pain | Change in Numeric Rating Scale (NRS) of pain from baseline to 4 weeks post treatment will be compared between treatment and control groups. | Baseline, 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
knee